Literature DB >> 26272278

Quality of life and nutritional consequences after aboral pouch reconstruction following total gastrectomy for gastric cancer: randomized controlled trial CCG1101.

Yuichi Ito1, Takaki Yoshikawa2, Michitaka Fujiwara3, Hiroshi Kojima4, Takanori Matsui4, Yoshinari Mochizuki5, Haruhiko Cho2, Toru Aoyama2, Seiji Ito1, Kazunari Misawa1, Hiroshi Nakayama6, Yuki Morioka7, Akiharu Ishiyama8, Chie Tanaka3, Satoshi Morita9, Junichi Sakamoto10, Yasuhiro Kodera11.   

Abstract

BACKGROUND: Total gastrectomy has detrimental effects on postoperative nutritional status and quality of life (QOL), but it is often unavoidable in the treatment of gastric cancer. Roux-en-Y (RY) is the most common reconstruction method following total gastrectomy. Trials to explore other means of reconstruction have been conducted but have failed to identify a method that is globally accepted.
METHODS: Aboral pouch reconstruction (AP), in which an anisoperistaltic jejunal pouch is created in the Y limb of the RY reconstruction, is considered effective and technically feasible. A prospective randomized trial was conducted to compare AP with RY. Gastric cancer patients requiring total gastrectomy for R0 resection were randomly assigned during surgery to receive either RY (n = 51) or AP (n = 49). Postoperative QOL as assessed by the EORTC QLQ-C30 and STO22, body composition, and morbidity were compared between the two reconstruction methods. The physical functioning score of the QLQ-C30 was selected as the primary endpoint.
RESULTS: The incidences of postoperative complications were similar between the two groups (29 % in the RY group and 27 % in the AP group). No significant difference was observed in the physical functioning score, and the superiority of AP was demonstrated only for the nausea and vomiting score at 12 months (p = 0.041) and the reflux score at 1 month (p = 0.036). No significant differences were observed in body composition or serum biochemistry.
CONCLUSIONS: Although AP was safely implemented, no increased benefits in nutritional or QOL-related parameters were observed for this method over RY within 12 months postoperatively.

Entities:  

Keywords:  Body composition; Jejunal pouch; Patient-reported outcome; Reconstruction; Total gastrectomy

Mesh:

Year:  2015        PMID: 26272278     DOI: 10.1007/s10120-015-0529-5

Source DB:  PubMed          Journal:  Gastric Cancer        ISSN: 1436-3291            Impact factor:   7.370


  26 in total

1.  Emptying of the jejunal pouch and Roux-en-Y limb after total gastrectomy--a randomised, prospective study.

Authors:  M K Iivonen; M O Koskinen; T J Ikonen; M J Matikainen; M K Jivonen
Journal:  Eur J Surg       Date:  1999-08

2.  The domain structure of the EORTC QLQ-STO22 supported by Japanese validation data.

Authors:  Satoshi Morita; Adrian A Kaptein; Koji Oba; Junichi Sakamoto
Journal:  Psychooncology       Date:  2008-05       Impact factor: 3.894

3.  A cross-validation of the European Organization for Research and Treatment of Cancer QLQ-C30 (EORTC QLQ-C30) for Japanese with lung cancer.

Authors:  K Kobayashi; F Takeda; S Teramukai; I Gotoh; H Sakai; S Yoneda; Y Noguchi; H Ogasawara; K Yoshida
Journal:  Eur J Cancer       Date:  1998-05       Impact factor: 9.162

4.  Japanese gastric cancer treatment guidelines 2010 (ver. 3).

Authors: 
Journal:  Gastric Cancer       Date:  2011-06       Impact factor: 7.370

5.  Characteristics and clinical relevance of postgastrectomy syndrome assessment scale (PGSAS)-45: newly developed integrated questionnaires for assessment of living status and quality of life in postgastrectomy patients.

Authors:  Koji Nakada; Masami Ikeda; Masazumi Takahashi; Shinichi Kinami; Masashi Yoshida; Yoshikazu Uenosono; Yoshiyuki Kawashima; Atsushi Oshio; Yoshimi Suzukamo; Masanori Terashima; Yasuhiro Kodera
Journal:  Gastric Cancer       Date:  2014-02-11       Impact factor: 7.370

6.  Pouch versus esophagojejunostomy after total gastrectomy: a randomized clinical trial.

Authors:  H Troidl; J Kusche; K H Vestweber; E Eypasch; U Maul
Journal:  World J Surg       Date:  1987-12       Impact factor: 3.352

7.  Changes in body composition after gastrectomy: results of a controlled, prospective clinical trial.

Authors:  B Liedman; H Andersson; I Bosaeus; I Hugosson; L Lundell
Journal:  World J Surg       Date:  1997-05       Impact factor: 3.352

8.  Assessment of quality of life after gastrectomy using EORTC QLQ-C30 and STO22.

Authors:  Daisuke Kobayashi; Yasuhiro Kodera; Michitaka Fujiwara; Masahiko Koike; Goro Nakayama; Akimasa Nakao
Journal:  World J Surg       Date:  2011-02       Impact factor: 3.352

9.  Loss of Lean Body Mass as an Independent Risk Factor for Continuation of S-1 Adjuvant Chemotherapy for Gastric Cancer.

Authors:  Toru Aoyama; Taiichi Kawabe; Hirohito Fujikawa; Tsutomu Hayashi; Takanobu Yamada; Kazuhito Tsuchida; Norio Yukawa; Takashi Oshima; Yasushi Rino; Munetaka Masuda; Takashi Ogata; Haruhiko Cho; Takaki Yoshikawa
Journal:  Ann Surg Oncol       Date:  2014-12-17       Impact factor: 5.344

Review 10.  Pouch vs. no pouch following total gastrectomy: meta-analysis and systematic review.

Authors:  Ralf Gertler; Robert Rosenberg; Marcus Feith; Tibor Schuster; Helmut Friess
Journal:  Am J Gastroenterol       Date:  2009-08-11       Impact factor: 10.864

View more
  7 in total

1.  Laparoscopy-assisted distal gastrectomy versus laparoscopy-assisted total gastrectomy with D2 lymph node dissection for middle-third advanced gastric cancer.

Authors:  Zhengyan Li; Gang Ji; Bin Bai; Deliang Yu; Yezhou Liu; Bo Lian; Qingchuan Zhao
Journal:  Surg Endosc       Date:  2017-11-02       Impact factor: 4.584

2.  Identification of potential hub genes of gastric cancer.

Authors:  Xu-Dong Zhou; Ya-Wei Qu; Li Wang; Fu-Hua Jia; Peng Chen; Yin-Pu Wang; Hai-Feng Liu
Journal:  Medicine (Baltimore)       Date:  2022-10-14       Impact factor: 1.817

3.  The investigation of diet recovery after distal gastrectomy.

Authors:  Tae-Han Kim; Young-Joon Lee; Kyungsoo Bae; Ji-Ho Park; Soon-Chan Hong; Eun-Jung Jung; Young-Tae Ju; Chi-Young Jeong; Tae-Jin Park; Miyeong Park; Ji Eun Kim; Sang-Ho Jeong
Journal:  Medicine (Baltimore)       Date:  2019-10       Impact factor: 1.817

4.  Anlotinib combined with SOX regimen (S1 (tegafur, gimeracil and oteracil porassium capsules) + oxaliplatin) in treating stage IV gastric cancer: study protocol for a single-armed and single-centred clinical trial.

Authors:  Juan Wang; Dong Xue Wu; Lu Meng; Gang Ji
Journal:  BMJ Open       Date:  2020-06-03       Impact factor: 2.692

5.  iTRAQ‑based proteomics analysis of the therapeutic effects of combined anticancer bioactive peptides and oxaliplatin on gastric cancer cells.

Authors:  Yanan Xu; Xian Li; Xiulan Su
Journal:  Oncol Rep       Date:  2019-11-11       Impact factor: 3.906

6.  Long-term effects of an oral elemental nutritional supplement on post-gastrectomy body weight loss in gastric cancer patients (KSES002).

Authors:  Yutaka Kimura; Kazuhiro Nishikawa; Kentaro Kishi; Kentaro Inoue; Jin Matsuyama; Yusuke Akamaru; Shigeyuki Tamura; Junji Kawada; Tomono Kawase; Ryohei Kawabata; Yoshiyuki Fujiwara; Hitoshi Kanno; Takeshi Yamada; Toshio Shimokawa; Hiroshi Imamura
Journal:  Ann Gastroenterol Surg       Date:  2019-10-10

7.  Intracorporeal bi-directional pouch jejunojejunostomy following Roux-en-Y anastomosis: a simple reconstruction technique using an endoscopic linear stapler.

Authors:  Amy Kim; Chang Seok Ko; Byung Sik Kim; Hee Sung Kim
Journal:  Wideochir Inne Tech Maloinwazyjne       Date:  2021-04-30       Impact factor: 1.195

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.